Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a TB Endemic Region.
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2016
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 22 Jul 2016 Status changed from active, no longer recruiting to completed.
- 11 Jul 2013 Planned End Date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.